<DOC>
	<DOCNO>NCT00550329</DOCNO>
	<brief_summary>The objective study determine bioequivalence Glipizide GITS ( Glucotrol XL ) 2.5 mg tablet manufacture Brooklyn , New York facility versus tablet manufacture facility Barceloneta , Puerto Rico .</brief_summary>
	<brief_title>Bioequivalence Study Of Glucotrol XL 2.5 Mg Tablets</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glipizide</mesh_term>
	<criteria>1 . Healthy male and/or female subject age 18 55 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test ) . Subjects age 21 year must consent either parent guardian country requirement . 2 . Body Mass Index ( BMI ) approximately 18 30 kg/m2 ; total body weight &gt; 45 kg ( 99 lb ) . 3 . Evidence personally sign date informed consent document indicate subject ( legally acceptable representative ) inform pertinent aspect trial . 4 . Subjects willing able comply schedule visit , treatment plan , laboratory test study procedure . 1 . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . 2 . Any condition possibly affect drug absorption ( e.g. , gastrectomy ) . 3 . A positive urine drug screen . 4 . History regular alcohol consumption exceed 7 drinks/week female 14 drinks/week men ( 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) hard liquor ) within 6 month screen . 5 . History evidence habitual tobacco nicotinecontaining product within 3 month screen positive urine serum cotinine test . 6 . Treatment investigational drug within 30 day precede first dose study medication . 7 . 12lead ECG demonstrate QTc &gt; 450 msec Screening . 8 . Sitting blood pressure ? 140 mm Hg systolic ? 90 mm Hg diastolic single measurement [ confirm single repeat , necessary ] follow least 5 minute rest Screening . 9 . Pregnant nursing female ; female childbearing potential unwilling unable use acceptable method nonhormonal contraception outline protocol least 14 day prior first dose study medication completion followup procedure . 10 . Use prescription nonprescription drug , vitamin dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose study medication . Herbal supplement hormonal method contraception ( include oral transdermal contraceptive , injectable progesterone , progestin subdermal implant , progesteronereleasing IUDs , postcoital contraceptive method ) hormone replacement therapy must discontinue 28 day prior first dose study medication . DepoProveraï¿½ must discontinue least 6 month prior first dose study medication . As exception , acetaminophen may use dos ? 1g/day . Other exception may grant qualified member Pfizer study management . 11 . Blood donation approximately 1 pint ( 500 mL ) within 56 day prior dose . 12 . Unwilling unable comply Lifestyle guideline describe protocol . 13 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2008</verification_date>
</DOC>